Duke University

Immunolight, LLC

The University of North Carolina at Chapel Hill

Johns Hopkins University

Other

Uwm Research Foundation, Inc.

Gooden, David

Spector, Neil, L.

Xia, Wenle

Toone, Eric, J.

Walder, Harold

Beyer, Wayne, F.

Soderblom, Erik, J.

Eric John Toone

Jonathan S Stamler

Pei Zhou

Richard S Stack

Frederic Avery Bourke, Jr

David M Gooden

Robert A Nicholas

Harold Walder

Tuan Vo-Dinh

Joshua Hare

Frank Navas, Iii

Andrew J Gow

Xiaofei Liang

Ramesh Gopalaswamy

Zakaryae Fathi

Michael J Therien

Ian Nicholas Stanton

Joshua T Stecher

James Clayton

Mitchell Anthony deLong

Wayne F Beyer

Jennifer Ann Ayres

Diane Renee Fels

Mark DeWhirst

Joseph A Herbert

Katherine Sarah Hansen

Dave Gooden

Xin Chen

Neil Lee Spector

Wayne F Beyer, Jr

David L Epstein

Ching-Hong Yang

Virginia Byers Kraus

Robert L Clark

Wenle Xia

Erik J Soderblom

Harinath Chakrapani

Phil Snyder

Piotr Marszalek

Amy Lynn McNulty

Phillip W Snyder

Pratap Challa

Frederic A Bourke

Jennifer Ayres

Frank Iii Navas

Zakarayae Fathi

Disclosed are compounds of formulae: and pharmaceutically acceptable salts thereof, wherein the variables, R, R, R, R, R, R, R, R, R, R, R, R, R, R, n, and m are defined herein. These compounds are useful for treating Gram-negative bacteria infections. Also disclosed are methods of making these compounds.

Benzoylglycine derivatives and methods of making and using same

Psoralen compounds of compounds having formulae 1A-10A, 1B-10B, 1C-10C, 1D-10D, 1E-10E, 1F-10F, 1G-10G, and 1H-5H as shown in FIG., and pharmaceutically acceptable salts thereof;

Methods and systems for treating cell proliferation disorders with psoralen derivatives

Disclosed are compounds of formulae: and pharmaceutically acceptable salts thereof, wherein the variables, R, R, R, R, R, R, R, R, R, R, R, R, R, R, n, and m are defined herein. These compounds are useful for treating Gram-negative bacteria infections. Also disclosed are methods of making these compounds. 

Disclosed are compounds of formulae: (I), and (II) and pharmaceutically acceptable salts thereof, wherein the variables, R, R, R, R, R, R, R, R, R, R, R, D, Q, Y, X, X, X, and Xare defined herein. These compounds are useful for treating Gram-negative bacteria infections. 

Substituted hydroxamic acid compounds

Disclosed are compounds of formulae (I), (II), and (II)I: and pharmaceutically acceptable salts thereof, wherein the variables, R, R, R, R, R, L, D, Q, Y, X, and Z are defined herein. These compounds are useful for treating Gram-negative bacteria infections. 

Ethynylbenzene derivatives

Disclosed are compounds of formulae (I) and (II) and pharmaceutically acceptable salts thereof, wherein the variables, R, R, R, R, Y, Z, X, R, R, R, R, Y, Z, X, and Xare defined herein. These compounds are useful for treating Gram-negative bacteria infections, such asbacterial infections. 

Antibacterial compounds

Disclosed are compounds of formulae: (I) and pharmaceutically acceptable salts thereof, wherein the variables, R, R, Y, and Z are defined herein. These compounds are useful for treating Gram-negative bacteria infections. 

2-piperidinyl substituted N,3-dihydroxybutanamides

A polymerizable composition includes at least one monomer, a photoinitiator capable of initiating polymerization of the monomer when exposed to light, and a phosphor capable of producing light when exposed to radiation (typically X-rays). The material is particularly suitable for bonding components at ambient temperature in situations where the bond joint is not accessible to an external light source. An associated method includes: placing a polymerizable adhesive composition, including a photoinitiator and energy converting material, such as a down-converting phosphor, in contact with at least two components to be bonded to form an assembly; and, irradiating the assembly with radiation at a first wavelength, capable of conversion (down-conversion by the phosphor) to a second wavelength capable of activating the photoinitiator, to prepare items such as inkjet cartridges, wafer-to-wafer assemblies, semiconductors, integrated circuits, and the like.

Adhesive bonding composition and method of use

Methods for the treatment of a cell proliferation disease or disorder in a subject, involving applying a psoralen derivative lacking a DNA cross-linking motif to cancer cells, applying a psoralen or a derivative thereof and lapatinib, or applying a psoralen or derivative thereof and neratinib, to a subject and further applying initiation radiation energy form an energy source.

Use of psoralen derivatives and combination therapy for treatment of cell proliferation disorders

A method of reducing virulence in a bacterium comprising at least one of a GacS/GacA-type system, a HrpX/HrpY-type system, a T3SS-type system, and a Rsm-type system, the method comprising contacting the bacterium with an effective amount of a compound described herein.

Methods of reducing virulence in bacteria

The present invention relates to methods of treatment of pulmonary disorders associated with hypoxemia and/or smooth muscle constriction and/or inflammation; treatment of cardiac and blood disorders; treatment of patient in need of improved oxygenation, blood flow of and/or thinning of blood and method of screening drugs that increase level of nitrosoglutathione in airway lining fluid.

Methods for treating cardio pulmonary diseases with NO group compounds

Growing community of inventors

Durham, NC, United States of America

Eric John Toone